2024 年 59 巻 1 号 p. 1-5
A preliminary survey for cases treated with intravenous immunoglobulin (IVIG) for Antibody-mediated rejection (AMR) in Japan was performed in 2022. Three cases treated with IVIG were reported. A secondary survey on the three cases was conducted in this study.
Intestine transplantation was performed in 42 cases from 2001 to 2022 in Japan, and IVIG was used in 3 of these cases (7%) for AMR that developed after transplantation. Five g of IVIG per dose was administrated, and the duration of administration was 6-10 days.
IVIG administration may be necessary as a therapeutic agent in intestine transplantation because of the high incidence of chronic rejection and its significant impact on prognosis. Therefore, we hope for national insurance coverage for IVIG.
